Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE In CDF Rethink Says OK To Bosulif For General NHS Use In CML

Executive Summary

Pfizer Inc.'s Bosulif (bosutinib) will now become generally available on the UK's publicly-funded NHS for use in certain types of chronic myeloid leukemia after NICE reassessed the tyrosine kinase inhibitor in light of new data and a bigger pro-offered price discount from its manufacturer. The drug was previously only available through the country's controversial Cancer Drugs Fund (CDF).


Related Content

Back to 2010: England's New CDF To Go Ahead
Pfizer faces more Bosulif bother as NICE issues final no


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts